What the trial was testing
The SURPASS-2 enrolled 1,879 patients with type 2 diabetes. The study was sponsored by Eli Lilly and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
More weight loss and bigger blood-sugar drops with tirzepatide than semaglutide.
New England Journal of Medicine · 2021 · NCT03987919
These findings — that average weight loss with the highest tirzepatide dose vs. weekly semaglutide over 40 weeks — were published in the New England Journal of Medicine and represent the headline result of the study.
Researchers tracked outcomes across 1,879 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with type 2 diabetes, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Tirzepatide (Mounjaro) is FDA-approved for type 2 diabetes and available now. The same drug is sold as Zepbound for weight management in adults without diabetes. Side effects are mostly nausea and stomach upset that ease over time. Ask your doctor whether tirzepatide or semaglutide is the better starting point for you.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open type 2 diabetes trials
Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients
The efficacy, safety and post-treatment disease control will be compared between groups of continuous subcutaneous Beinaglutide infusion and continuous subcutaneous insulin infusion (CSII) in adult patients with newly diagnosed type 2 diabetes.
Enhancing Diabetes Care: Exposome &Amp; Sensors
The study aims to integrate various data types, such as electronic health records, wearable device data, and environmental data, to create a comprehensive, personalized diabetes care model. The study will focus on people with type 2 diabetes living in specified vulnerable zip codes.